The Priority Review

Category

Clinical trials

Trial starts, readouts, holds and designs.

267 stories · page 20 of 23

Stories

  1. Janssen posts results of long-term aticaprant study in 871 participants

    Janssen posted results of the open-label VENTURA-LT study of aticaprant in major depressive disorder on 2026-10-06. The study enrolled 871 participants and ended early, and the record says the results have limited interpretive value.

  2. New Phase 3 trials registered, week of September 28, 2026: 9 industry trials

    Industry sponsors registered 9 Phase 3 trials on ClinicalTrials.gov in the week of September 28 to October 4, 2026. They plan to enroll 7,514 participants in all; the largest, GlaxoSmithKline's mRNA Seasonal Flu vaccine trial, plans to enroll 3,000.

  3. Phase 3 results posted, week of September 28, 2026: 8 industry trials

    Industry sponsors posted results for 8 Phase 3 trials on ClinicalTrials.gov in the week of September 28 to October 4, 2026. Together the trials enrolled 3,200 participants; the largest, Teva Pharmaceuticals USA's Estradiol trial, enrolled 1,050.

  4. New Phase 3 trials registered, week of October 5, 2026: 11 industry trials

    Industry sponsors registered 11 Phase 3 trials on ClinicalTrials.gov in the week of October 5 to 11, 2026. They plan to enroll 6,829 participants in all; the largest, Shanghai Henlius Biotech's NCT07865910 trial, plans to enroll 1,438.

  5. Phase 3 results posted, week of October 5, 2026: 12 industry trials

    Industry sponsors posted results for 12 Phase 3 trials on ClinicalTrials.gov in the week of October 5 to 11, 2026. Together the trials enrolled 5,329 participants; the largest, Sanofi's AERIFY-2 trial, enrolled 1,234.

  6. Amgen registers Phase 3 trial of maridebart cafraglutide versus semaglutide in type 2 diabetes

    The study, NCT07866066, plans to enroll 1300 participants and start on November 2, 2026. It plans to compare maridebart cafraglutide once monthly versus semaglutide once weekly as add-on therapy to metformin with or without a sodium-glucose cotransporter-2 inhibitor.

  7. Shanghai Henlius Biotech registers Phase II/III study of HLX37 in first-line NSCLC

    The study, first posted on ClinicalTrials.gov on October 8, 2026, plans to enroll 1438 participants and plans to begin recruiting on November 30, 2026. It compares two doses of HLX37 combined with chemotherapy to pembrolizumab plus chemotherapy in advanced non-small cell lung cancer.

  8. DBV Technologies posts results of Phase 3 Viaskin Peanut study

    The REALISE study evaluated Viaskin Peanut 250 μg in 393 peanut-allergic children aged 4 to 11 years in a 6-month randomized, double-blind, placebo-controlled Phase III trial. The study began on October 25, 2016, with primary completion on September 22, 2017.

  9. PTC Therapeutics posts results of Phase 3 ataluren safety study in Duchenne muscular dystrophy

    Results for the open-label safety study of ataluren (PTC124) in 265 participants with nonsense mutation dystrophinopathy were first posted on ClinicalTrials.gov on October 8, 2026. The study, which began on November 22, 2010 and reached primary completion on February 10, 2026, was terminated before completion.

  10. Sagimet registers Phase 3 trial of denifanstat in moderate to severe acne vulgaris

    The study, first posted on ClinicalTrials.gov on October 7, 2026, plans to enroll 800 participants and begin in October 2026. After a 12-week treatment phase, about 530 participants may consent to a 40-week open-label extension.

  11. Sanofi posts results of Phase 3 MenACYW conjugate vaccine study in infants and toddlers

    Results for the Phase 3 study comparing MenACYW conjugate vaccine (MenQuadfi) with Nimenrix were first posted on ClinicalTrials.gov on October 7, 2026. The 840-participant, randomized, triple-masked trial, completed on November 14, 2025, evaluated non-inferiority of the immunological response after a 1+1 vaccination schedule in healthy infants and toddlers.

  12. Instituto Grifols posts results of Phase II/III trial of plasma-derived AT-III concentrate

    The study enrolled 3 participants with Antithrombin III Deficiency and began on April 15, 2008. It was terminated after primary completion in December 2011.